BioCentury
ARTICLE | Company News

Hemispherx, Aventis deal

January 31, 2000 8:00 AM UTC

HEB received a grant from Rhone-Poulenc SA, which merged with Hoechst AG to form AVE, to develop HEB's nucleic acid therapeutics to treat chronic fatigue syndrome (CFS) and other indications. HEB sai...